BICARA THERAPEUTICS INC (BCAX) Stock Fundamental Analysis

NASDAQ:BCAX • US0554771032

14.21 USD
+0.15 (+1.07%)
At close: Feb 13, 2026
14.21 USD
0 (0%)
After Hours: 2/13/2026, 8:00:01 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

3

Taking everything into account, BCAX scores 3 out of 10 in our fundamental rating. BCAX was compared to 522 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for BCAX as it has an excellent financial health rating, but there are worries on the profitability. BCAX does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • BCAX had negative earnings in the past year.
  • BCAX had a negative operating cash flow in the past year.
BCAX Yearly Net Income VS EBIT VS OCF VS FCFBCAX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2022 2023 2024 -20M -40M -60M -80M

1.2 Ratios

  • BCAX has a Return On Assets of -28.61%. This is in the better half of the industry: BCAX outperforms 67.88% of its industry peers.
  • BCAX has a Return On Equity of -30.17%. This is in the better half of the industry: BCAX outperforms 75.72% of its industry peers.
Industry RankSector Rank
ROA -28.61%
ROE -30.17%
ROIC N/A
ROA(3y)-200.05%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BCAX Yearly ROA, ROE, ROICBCAX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2022 2023 2024 0 200 -200 -400

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for BCAX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BCAX Yearly Profit, Operating, Gross MarginsBCAX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2022 2023 2024

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. Health

2.1 Basic Checks

  • The number of shares outstanding for BCAX has been increased compared to 1 year ago.
  • BCAX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
BCAX Yearly Shares OutstandingBCAX Yearly Shares OutstandingYearly Shares Outstanding 2022 2023 2024 10M 20M 30M 40M 50M
BCAX Yearly Total Debt VS Total AssetsBCAX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

  • An Altman-Z score of 19.94 indicates that BCAX is not in any danger for bankruptcy at the moment.
  • BCAX has a better Altman-Z score (19.94) than 89.87% of its industry peers.
  • There is no outstanding debt for BCAX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 19.94
ROIC/WACCN/A
WACCN/A
BCAX Yearly LT Debt VS Equity VS FCFBCAX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2022 2023 2024 0 100M 200M 300M 400M

2.3 Liquidity

  • A Current Ratio of 14.14 indicates that BCAX has no problem at all paying its short term obligations.
  • With an excellent Current ratio value of 14.14, BCAX belongs to the best of the industry, outperforming 90.44% of the companies in the same industry.
  • A Quick Ratio of 14.14 indicates that BCAX has no problem at all paying its short term obligations.
  • Looking at the Quick ratio, with a value of 14.14, BCAX belongs to the top of the industry, outperforming 90.44% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 14.14
Quick Ratio 14.14
BCAX Yearly Current Assets VS Current LiabilitesBCAX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

0

3. Growth

3.1 Past

  • The earnings per share for BCAX have decreased strongly by -302.87% in the last year.
EPS 1Y (TTM)-302.87%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%58.13%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, BCAX will show a small growth in Earnings Per Share. The EPS will grow by 5.67% on average per year.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y3.83%
EPS Next 2Y-7.93%
EPS Next 3Y-7.61%
EPS Next 5Y5.67%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
BCAX Yearly Revenue VS EstimatesBCAX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2028 2029 2030 2031 2032 2033 500M 1B
BCAX Yearly EPS VS EstimatesBCAX Yearly EPS VS EstimatesYearly EPS VS Estimates 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 2 -2 4

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for BCAX. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for BCAX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BCAX Price Earnings VS Forward Price EarningsBCAX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BCAX Per share dataBCAX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6

4.3 Compensation for Growth

  • BCAX's earnings are expected to decrease with -7.61% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-7.93%
EPS Next 3Y-7.61%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • BCAX does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

BICARA THERAPEUTICS INC

NASDAQ:BCAX (2/13/2026, 8:00:01 PM)

After market: 14.21 0 (0%)

14.21

+0.15 (+1.07%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-10
Earnings (Next)03-24
Inst Owners86.34%
Inst Owner Change-88.46%
Ins Owners1.53%
Ins Owner Change4.76%
Market Cap778.42M
Revenue(TTM)N/A
Net Income(TTM)-121.52M
Analysts82.22
Price Target31.42 (121.11%)
Short Float %19.75%
Short Ratio15.29
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-2.91%
Min EPS beat(2)-19.6%
Max EPS beat(2)13.77%
EPS beat(4)1
Avg EPS beat(4)-21.18%
Min EPS beat(4)-60.69%
Max EPS beat(4)13.77%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-5.44%
PT rev (3m)-4.18%
EPS NQ rev (1m)0.56%
EPS NQ rev (3m)-16.47%
EPS NY rev (1m)0.41%
EPS NY rev (3m)-9.22%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.93
P/tB 1.93
EV/EBITDA N/A
EPS(TTM)-2.24
EYN/A
EPS(NY)-3.09
Fwd EYN/A
FCF(TTM)-2.06
FCFYN/A
OCF(TTM)-2.06
OCFYN/A
SpS0
BVpS7.35
TBVpS7.35
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -28.61%
ROE -30.17%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-200.05%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 106.49%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 14.14
Quick Ratio 14.14
Altman-Z 19.94
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)1710.33%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-302.87%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%58.13%
EPS Next Y3.83%
EPS Next 2Y-7.93%
EPS Next 3Y-7.61%
EPS Next 5Y5.67%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-106.55%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-93.65%
EBIT Next 3Y-38.39%
EBIT Next 5YN/A
FCF growth 1Y-61.9%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-63.83%
OCF growth 3YN/A
OCF growth 5YN/A

BICARA THERAPEUTICS INC / BCAX FAQ

What is the ChartMill fundamental rating of BICARA THERAPEUTICS INC (BCAX) stock?

ChartMill assigns a fundamental rating of 3 / 10 to BCAX.


What is the valuation status of BICARA THERAPEUTICS INC (BCAX) stock?

ChartMill assigns a valuation rating of 0 / 10 to BICARA THERAPEUTICS INC (BCAX). This can be considered as Overvalued.


What is the profitability of BCAX stock?

BICARA THERAPEUTICS INC (BCAX) has a profitability rating of 1 / 10.


How financially healthy is BICARA THERAPEUTICS INC?

The financial health rating of BICARA THERAPEUTICS INC (BCAX) is 8 / 10.